Hunan Jingfeng Pharmaceutical Total Liabilities
Hunan Jingfeng Pharmaceutical total liabilities. Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) has total liabilities worth CN¥915.74 Million CNY (≈ $134.00 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Hunan Jingfeng Pharmaceutical to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hunan Jingfeng Pharmaceutical (1995–2024)
Total liabilities of Hunan Jingfeng Pharmaceutical from 1995 to 2024. This chart illustrates how Hunan Jingfeng Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore Hunan Jingfeng Pharmaceutical strategic investment ratio to see how much of total assets are deployed in long-term investments.
Hunan Jingfeng Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Hunan Jingfeng Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Phreesia Inc
NYSE:PHR
|
USA | $103.14 Million |
|
Ningbo Sinyuan ZM Technology Co. Ltd. A
SHE:301398
|
China | CN¥862.44 Million |
|
Weihai Honglin Electronic Co. Ltd. A
SHE:301439
|
China | CN¥2.11 Billion |
|
Ridley Corporation Ltd
AU:RIC
|
Australia | AU$1.10 Billion |
|
Priortech
TA:PRTC
|
Israel | ILA123.21 Million |
|
VBG Group AB (publ)
ST:VBG-B
|
Sweden | Skr3.56 Billion |
|
Hemnet Group AB
ST:HEM
|
Sweden | Skr1.14 Billion |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
Brazil | R$35.19 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Hunan Jingfeng Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hunan Jingfeng Pharmaceutical balance sheet assets.
Liquidity & Leverage Metrics
Hunan Jingfeng Pharmaceutical Total Liabilities Ratios Explained
Hunan Jingfeng Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 24.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Jingfeng Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Jingfeng Pharmaceutical (1995–2024)
The table below shows the annual total liabilities of Hunan Jingfeng Pharmaceutical from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥955.11 Million ≈ $139.76 Million |
-21.33% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.65 Million |
-3.16% |
| 2022-12-31 | CN¥1.25 Billion ≈ $183.45 Million |
-14.40% |
| 2021-12-31 | CN¥1.46 Billion ≈ $214.31 Million |
-28.62% |
| 2020-12-31 | CN¥2.05 Billion ≈ $300.25 Million |
-14.80% |
| 2019-12-31 | CN¥2.41 Billion ≈ $352.41 Million |
+1.83% |
| 2018-12-31 | CN¥2.37 Billion ≈ $346.08 Million |
+4.24% |
| 2017-12-31 | CN¥2.27 Billion ≈ $332.01 Million |
-10.02% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.99 Million |
+111.16% |
| 2015-12-31 | CN¥1.19 Billion ≈ $174.75 Million |
+29.84% |
| 2014-12-31 | CN¥919.76 Million ≈ $134.59 Million |
+177.48% |
| 2013-12-31 | CN¥331.47 Million ≈ $48.50 Million |
-22.97% |
| 2012-12-31 | CN¥430.29 Million ≈ $62.96 Million |
+2.29% |
| 2011-12-31 | CN¥420.66 Million ≈ $61.56 Million |
+1.72% |
| 2010-12-31 | CN¥413.53 Million ≈ $60.51 Million |
-39.55% |
| 2009-12-31 | CN¥684.14 Million ≈ $100.11 Million |
+5.16% |
| 2008-12-31 | CN¥650.60 Million ≈ $95.20 Million |
+36.27% |
| 2007-12-31 | CN¥477.43 Million ≈ $69.86 Million |
-1.78% |
| 2006-12-31 | CN¥486.08 Million ≈ $71.13 Million |
-4.78% |
| 2005-12-31 | CN¥510.48 Million ≈ $74.70 Million |
-7.20% |
| 2004-12-31 | CN¥550.11 Million ≈ $80.50 Million |
-2.40% |
| 2003-12-31 | CN¥563.64 Million ≈ $82.48 Million |
+63.86% |
| 2002-12-31 | CN¥343.98 Million ≈ $50.34 Million |
+180.86% |
| 2001-12-31 | CN¥122.47 Million ≈ $17.92 Million |
-37.95% |
| 2000-12-31 | CN¥197.38 Million ≈ $28.88 Million |
-4.42% |
| 1999-12-31 | CN¥206.51 Million ≈ $30.22 Million |
+184.70% |
| 1998-12-31 | CN¥72.54 Million ≈ $10.61 Million |
+58.70% |
| 1997-12-31 | CN¥45.70 Million ≈ $6.69 Million |
-35.37% |
| 1996-12-31 | CN¥70.71 Million ≈ $10.35 Million |
+98.97% |
| 1995-12-31 | CN¥35.54 Million ≈ $5.20 Million |
-- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more